作为严重COVID-19的标记物和潜在的治疗点的TLR2激活

Xianxian Mao1, Yijia Wu2,3,4, Xinyi Zhang5

  • 1Huankui Academy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China.

PubMed
概括

由SARS-CoV-2蛋白质激活的托尔类受体2 (TLR2) 驱动COVID-19高炎症和组织损伤. 针对TLR2可能为严重的COVID-19患者提供新的治疗策略.